RAPT [NASD]
RAPT Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.53 Insider Own0.30% Shs Outstand29.57M Perf Week9.13%
Market Cap331.35M Forward P/E- EPS next Y-3.82 Insider Trans- Shs Float28.81M Perf Month-34.05%
Income-69.20M PEG- EPS next Q-0.74 Inst Own93.40% Short Float4.88% Perf Quarter-35.68%
Sales3.80M P/S87.20 EPS this Y-15.30% Inst Trans0.57% Short Ratio4.48 Perf Half Y-62.97%
Book/sh5.68 P/B2.34 EPS next Y-25.70% ROA-35.10% Target Price54.43 Perf Year-39.79%
Cash/sh6.93 P/C1.92 EPS next 5Y- ROE-37.80% 52W Range9.85 - 43.26 Perf YTD-63.87%
Dividend- P/FCF- EPS past 5Y- ROI-37.10% 52W High-68.49% Beta-
Dividend %- Quick Ratio14.20 Sales past 5Y- Gross Margin- 52W Low38.31% ATR1.63
Employees83 Current Ratio14.20 Sales Q/Q-50.00% Oper. Margin- RSI (14)42.07 Volatility10.41% 11.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.10% Profit Margin- Rel Volume0.43 Prev Close13.27
ShortableYes LT Debt/Eq0.00 EarningsMar 10 BMO Payout- Avg Volume313.79K Price13.63
Recom1.90 SMA20-4.55% SMA50-28.23% SMA200-50.84% Volume25,162 Change2.71%
Dec-09-21Initiated JP Morgan Overweight $61
Aug-12-21Initiated SVB Leerink Outperform $49
Jun-21-21Initiated Piper Sandler Overweight $61
Jun-01-20Initiated H.C. Wainwright Buy $40
May-19-20Initiated Cantor Fitzgerald Overweight $37
Apr-13-20Initiated ROTH Capital Buy $38
Nov-25-19Initiated Wells Fargo Outperform $33
Nov-25-19Initiated UBS Buy $26
Nov-25-19Initiated BMO Capital Markets Outperform $35
May-11-22 09:15AM  
08:00AM  
May-09-22 05:15PM  
May-05-22 09:25AM  
May-04-22 08:00AM  
Apr-11-22 08:29AM  
Mar-28-22 08:00AM  
Mar-10-22 08:00AM  
Mar-01-22 11:05AM  
Feb-24-22 10:35AM  
Feb-09-22 08:00AM  
Feb-08-22 01:38PM  
Jan-04-22 08:00AM  
Nov-29-21 03:04PM  
Nov-10-21 06:05PM  
04:05PM  
Nov-09-21 04:01PM  
Nov-08-21 03:00PM  
08:00AM  
Oct-29-21 09:33AM  
Oct-25-21 04:10PM  
Oct-18-21 08:00AM  
Sep-30-21 09:15AM  
Sep-23-21 11:15AM  
Sep-20-21 08:00AM  
08:00AM  
Sep-10-21 04:59PM  
Sep-03-21 08:00AM  
Aug-11-21 08:00AM  
Aug-05-21 03:01PM  
Jul-28-21 01:08PM  
Jul-22-21 06:11AM  
Jun-18-21 12:24PM  
Jun-16-21 11:49AM  
06:55AM  
Jun-15-21 11:07PM  
02:07PM  
01:26PM  
08:40AM  
Jun-14-21 04:01PM  
12:44PM  
08:00AM  
07:11AM  
Jun-13-21 04:00PM  
Jun-07-21 08:46AM  
May-20-21 04:00PM  
May-19-21 08:36AM  
May-11-21 08:00AM  
May-06-21 03:01PM  
Apr-12-21 07:49AM  
Apr-08-21 05:02AM  
Mar-22-21 08:00AM  
Mar-11-21 08:00AM  
Mar-10-21 04:30PM  
Mar-03-21 08:00AM  
Feb-22-21 09:47AM  
04:11AM  
Feb-19-21 08:00AM  
Jan-07-21 04:30AM  
Jan-05-21 08:00AM  
Dec-28-20 10:16AM  
Dec-15-20 11:26PM  
Nov-23-20 08:00AM  
01:24AM  
Nov-16-20 08:00AM  
07:30AM  
Nov-15-20 07:30AM  
Nov-13-20 08:00AM  
Nov-11-20 09:43AM  
Oct-14-20 08:00AM  
Sep-27-20 10:25AM  
Sep-03-20 08:32AM  
08:00AM  
Sep-01-20 02:53PM  
Aug-13-20 10:47AM  
Aug-05-20 08:00AM  
Jul-23-20 08:14PM  
Jul-02-20 11:24AM  
Jun-18-20 04:05PM  
Jun-17-20 08:00AM  
Jun-04-20 07:49AM  
May-29-20 08:00AM  
May-26-20 08:00AM  
May-19-20 07:47AM  
May-18-20 07:55AM  
May-17-20 10:38AM  
May-15-20 08:00AM  
May-14-20 08:00AM  
08:00AM  
May-12-20 08:00AM  
Mar-30-20 08:00AM  
Mar-04-20 08:00AM  
Feb-19-20 08:00AM  
Feb-07-20 06:45AM  
Feb-04-20 05:43PM  
Jan-31-20 11:27AM  
Jan-07-20 08:00AM  
Dec-16-19 08:00AM  
Dec-11-19 08:00AM  
Dec-10-19 08:00AM  
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COLUMN GROUP II, LP10% OwnerMay 10Buy10.671,250,00013,339,3751,208,750May 12 05:29 PM
COLUMN GROUP II, LP10% OwnerMay 10Buy10.671,250,00013,339,3751,208,750May 12 05:28 PM
Young Rodney KBChief Financial OfficerMay 10Buy10.535,00052,65010,084May 12 05:00 PM
Robbins WendyeDirectorMay 10Buy10.682,50026,7024,000May 12 04:59 PM
Robbins WendyeDirectorMay 10Buy11.244,50050,58013,800May 12 04:59 PM
Brockstedt Dirk G.Chief Scientific OfficerMay 04Sale15.0572010,83619,812May 05 01:28 PM
Brockstedt Dirk G.Chief Scientific OfficerApr 11Option Exercise6.182,64716,35822,459Apr 12 07:05 PM
HO WILLIAMChief Medical OfficerApr 11Option Exercise12.0092011,04054,306Apr 12 07:04 PM
Brockstedt Dirk G.Chief Scientific OfficerApr 11Sale23.052,64761,01319,812Apr 12 07:05 PM
HO WILLIAMChief Medical OfficerApr 06Sale22.963,00068,88053,386Apr 07 03:25 PM
HO WILLIAMChief Medical OfficerApr 04Option Exercise6.306954,37856,386Apr 04 07:29 PM
Brockstedt Dirk G.Chief Scientific OfficerMar 11Option Exercise6.182,64816,36522,460Mar 14 04:53 PM
Brockstedt Dirk G.Chief Scientific OfficerMar 11Sale23.912,64863,31419,812Mar 14 04:53 PM
HO WILLIAMChief Medical OfficerFeb 28Sale18.793,00056,37055,691Feb 28 08:34 PM
Brockstedt Dirk G.Chief Scientific OfficerFeb 11Option Exercise6.182,64716,35822,459Feb 14 03:09 PM
Brockstedt Dirk G.Chief Scientific OfficerFeb 11Sale22.472,64759,47819,812Feb 14 03:09 PM
HO WILLIAMChief Medical OfficerFeb 08Option Exercise9.558077,70658,691Feb 09 06:05 PM
HO WILLIAMChief Medical OfficerJan 13Sale30.673,00092,01057,884Jan 14 04:11 PM
Brockstedt Dirk G.Chief Scientific OfficerJan 11Option Exercise6.182,64816,36522,460Jan 13 12:27 PM
Brockstedt Dirk G.Chief Scientific OfficerJan 11Sale32.162,64885,16019,812Jan 13 12:27 PM
HO WILLIAMChief Medical OfficerJan 05Sale40.002,00080,00060,884Jan 06 02:45 PM
HO WILLIAMChief Medical OfficerJan 04Option Exercise8.545,77849,33162,884Jan 06 02:45 PM
Brockstedt Dirk G.Chief Scientific OfficerDec 10Option Exercise6.302,64716,67622,459Dec 13 03:47 PM
Brockstedt Dirk G.Chief Scientific OfficerDec 10Sale30.882,64781,73919,812Dec 13 03:47 PM
HO WILLIAMChief Medical OfficerDec 03Sale32.263,00096,78057,106Dec 06 01:28 PM
Brockstedt Dirk G.Chief Scientific OfficerNov 11Option Exercise6.302,64816,68222,460Dec 10 06:01 PM
Brockstedt Dirk G.Chief Scientific OfficerNov 11Sale35.692,64894,50719,812Dec 10 06:01 PM
Robbins WendyeDirectorOct 18Buy30.7050015,3509,300Oct 19 11:33 AM
Robbins WendyeDirectorOct 13Buy29.6940011,8768,800Oct 15 06:25 PM
HO WILLIAMChief Medical OfficerOct 13Sale29.693,00089,07060,106Oct 14 01:16 PM
Brockstedt Dirk G.Chief Scientific OfficerOct 11Option Exercise6.182,64716,35822,459Oct 12 02:48 PM
Brockstedt Dirk G.Chief Scientific OfficerOct 11Sale30.782,64781,47519,812Oct 12 02:48 PM
COLUMN GROUP II, LP10% OwnerSep 27Option Exercise26.939,239248,8187,500Sep 29 04:58 PM
COLUMN GROUP II, LP10% OwnerSep 27Sale34.579,239319,3970Sep 29 04:58 PM
HO WILLIAMChief Medical OfficerSep 20Sale40.002,00080,00063,106Sep 22 06:27 PM
HO WILLIAMChief Medical OfficerSep 17Sale38.972,00077,93063,106Sep 20 01:58 PM
COLUMN GROUP II, LP10% OwnerSep 15Sale37.3533,5351,252,4180Sep 16 05:16 PM
COLUMN GROUP II, LP10% OwnerSep 14Sale36.94147,6765,454,8000Sep 16 05:16 PM
COLUMN GROUP II, LP10% OwnerSep 13Sale35.2714,317504,94336,633Sep 14 05:31 PM
Brockstedt Dirk G.Chief Scientific OfficerSep 10Option Exercise6.182,64816,36522,460Sep 13 01:29 PM
COLUMN GROUP II, LP10% OwnerSep 10Sale35.1921,738765,00741,421Sep 14 05:31 PM
Brockstedt Dirk G.Chief Scientific OfficerSep 10Sale35.782,64894,74519,812Sep 13 01:29 PM
HO WILLIAMChief Medical OfficerSep 08Sale36.043,000108,12065,106Sep 09 07:36 PM
COLUMN GROUP II, LP10% OwnerSep 02Sale35.4337,1011,314,5520Sep 03 04:09 PM
COLUMN GROUP II, LP10% OwnerSep 01Sale35.2331,7491,118,59218,545Sep 03 04:09 PM
Robbins WendyeDirectorAug 24Buy30.9952516,2702,000Aug 25 09:08 PM
COLUMN GROUP II, LP10% OwnerAug 24Sale31.4222,867718,4130Aug 24 08:52 PM
Robbins WendyeDirectorAug 23Buy31.391,47546,2951,475Aug 25 09:08 PM
COLUMN GROUP II, LP10% OwnerAug 23Sale31.3468,3402,141,57011,418Aug 24 08:52 PM
Robbins WendyeDirectorAug 20Buy29.5360017,7168,400Aug 23 07:04 PM
COLUMN GROUP II, LP10% OwnerAug 20Sale30.084,539136,53334,076Aug 24 08:52 PM
HO WILLIAMChief Medical OfficerAug 16Sale32.071,00032,07068,106Aug 17 07:24 PM
Brockstedt Dirk G.Chief Scientific OfficerAug 11Option Exercise6.182,64716,35822,459Aug 12 05:27 PM
Brockstedt Dirk G.Chief Scientific OfficerAug 11Sale31.192,64782,56019,812Aug 12 05:27 PM
HO WILLIAMChief Medical OfficerAug 06Option Exercise12.003,69044,28069,106Aug 09 01:28 PM
HO WILLIAMChief Medical OfficerAug 04Option Exercise6.246944,33165,416Aug 06 01:22 PM
HO WILLIAMChief Medical OfficerAug 02Sale30.521,00030,52064,722Aug 03 06:05 PM
HO WILLIAMChief Medical OfficerJul 23Option Exercise6.268,19351,28365,722Jul 26 03:59 PM
HO WILLIAMChief Medical OfficerJul 15Sale30.231,00030,23057,529Jul 16 01:00 PM
Brockstedt Dirk G.Chief Scientific OfficerJul 12Option Exercise6.182,64816,36522,460Jul 13 02:35 PM
Brockstedt Dirk G.Chief Scientific OfficerJul 12Sale33.532,64888,78719,812Jul 13 02:35 PM
Robbins WendyeDirectorJul 07Buy30.181,00030,1807,800Jul 08 01:32 PM
HO WILLIAMChief Medical OfficerJul 01Sale31.751,00031,75058,529Jul 02 12:49 PM
Robbins WendyeDirectorJun 16Buy31.615158305Jun 21 05:06 PM
Robbins WendyeDirectorJun 16Buy31.5470022,0796,800Jun 21 05:06 PM
HO WILLIAMChief Medical OfficerJun 15Sale43.261,00043,26059,529Jun 17 01:23 PM
HO WILLIAMChief Medical OfficerJun 14Sale40.002,00080,00060,529Jun 16 06:53 PM
Brockstedt Dirk G.Chief Scientific OfficerJun 11Option Exercise6.182,64716,35822,459Jun 15 08:51 PM
Brockstedt Dirk G.Chief Scientific OfficerJun 11Sale18.552,64749,10219,812Jun 15 08:51 PM
HO WILLIAMChief Medical OfficerJun 01Sale19.501,00019,50062,529Jun 02 05:39 PM